Roivant Sciences Ltd. ROIV
Institutional shares held
505 Million
573K
calls
739K
puts
Total value of holdings
$5.13B
$5.83M
calls
$7.51M
puts
Market Cap
$7.27B
704,382,976
Shares Out.
Institutional ownership
71.67%
# of Institutions
332
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Qvt Financial LP New York, NY65.8MShares$679 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$640 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$493 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$455 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$365 Million0.01% of portfolio
-
Morgan Stanley New York, NY34.6MShares$357 Million0.03% of portfolio
-
State Street Corp Boston, MA20.8MShares$215 Million0.01% of portfolio
-
Rubric Capital Management LP New York, NY20MShares$206 Million3.91% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.5MShares$129 Million55.22% of portfolio
-
Two Seas Capital LP Rye, NY10.2MShares$105 Million19.7% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,635
-0.6%
|
$16,350
$10.74 P/Share
|
|
Feb 20
2025
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-1.22%
|
$109,450
$10.72 P/Share
|
|
Feb 20
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
100,000
-10.03%
|
$1,000,000
$10.65 P/Share
|
|
Feb 20
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+9.12%
|
$300,000
$3.85 P/Share
|
|
Feb 20
2025
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.06%
|
$109,450
$10.72 P/Share
|
|
Feb 20
2025
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-0.59%
|
$9,580
$10.72 P/Share
|
|
Feb 13
2025
|
Rakhi Kumar Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
227,500
-58.22%
|
$2,275,000
$10.43 P/Share
|
|
Feb 13
2025
|
Rakhi Kumar Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
187,500
+32.42%
|
$562,500
$3.85 P/Share
|
|
Feb 13
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
218,041
-19.56%
|
$2,180,410
$10.42 P/Share
|
|
Feb 13
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+21.2%
|
$900,000
$3.85 P/Share
|
|
Feb 12
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
217,384
-22.89%
|
$2,173,840
$10.53 P/Share
|
|
Feb 12
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+22.52%
|
$900,000
$3.85 P/Share
|
|
Jan 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,896
-0.7%
|
$20,856
$11.15 P/Share
|
|
Jan 23
2025
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
313
-0.31%
|
$3,443
$11.21 P/Share
|
|
Jan 23
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
2,386
+2.32%
|
-
|
|
Jan 23
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
306
-0.32%
|
$3,366
$11.21 P/Share
|
|
Jan 23
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,248
+1.3%
|
-
|
|
Jan 23
2025
|
Epperly Melissa B, |
SELL
Payment of exercise price or tax liability
|
Direct |
180
-0.45%
|
$1,980
$11.21 P/Share
|
|
Jan 23
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,672
+4.04%
|
-
|
|
Jan 23
2025
|
Vivek Ramaswamy > 10% Shareholder |
BUY
Bona fide gift
|
Indirect |
13,357,857
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
55.8M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 36.4M shares |
|---|---|
| Exercise of conversion of derivative security | 6.01M shares |
| Bona fide gift | 13.4M shares |
Sell / Disposition
151M
Shares
From
27
Insiders
| Payment of exercise price or tax liability | 929K shares |
|---|---|
| Other acquisition or disposition | 126M shares |
| Open market or private sale | 10.9M shares |
| Grant, award, or other acquisition | 38.7K shares |
| Bona fide gift | 13.4M shares |